ZLDI-8

立即咨询

ZLDI-8

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

667880-38-8

包装与价格：

包装	价格(元)
10mM (in 1mL DMSO)	询价
5mg	询价
10mg	询价
50mg	询价
100mg	询价

ZLDI-8 是一种 Notch 激活/切割酶 ADAM-17 抑制剂，可抑制 Notch 蛋白的切割。 ZLDI-8 降低促存活/抗凋亡和上皮间质转化 (EMT) 相关蛋白的表达。 ZLDI-8 还是一种竞争性且不可逆的酪氨酸磷酸酶 (Lyp) 抑制剂，IC50 为 31.6 μM，Ki 为 26.22 μM。 ZLDI-8 抑制 MHCC97-H 细胞的生长，IC50 为 5.32 μM。

Cas No.	667880-38-8
Canonical SMILES	O=C(/C(C(N1)=O)=C/C2=C(C)N(CCOC3=CC=C(C)C=C3C)C4=C2C=CC=C4)NC1=S
分子式	C24H23N3O3S
分子量	433.52
溶解度	62.5 mg/mL in DMSO
储存条件	Store at -20℃
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
产品描述	ZLDI-8 is a Notch activating/cleaving enzyme ADAM-17 inhibitor and inhibits the cleavage of Notch protein. ZLDI-8 decreases the expression of pro-survival/anti-apoptosis and epithelial-mesenchymal transition (EMT) related proteins. ZLDI-8 is also a competitive and irreversible tyrosine phosphatase (Lyp) inhibitor with an IC50 of 31.6 μM and a Ki of 26.22 μM. ZLDI-8 inhibits the growth of MHCC97-H cells with an IC50 of 5.32 μM[1][2]. Reference： [1]. Zhang Y, et al. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis. 2018 Jul 3;9(7):743. [2]. Hou X, et al. Fast identification of novel lymphoid tyrosine phosphatase inhibitors using target-ligand interaction-based virtual screening. J Med Chem. 2014 Nov 26;57(22):9309-22.